Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$6.75 USD
-0.07 (-1.03%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $6.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.75 USD
-0.07 (-1.03%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $6.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Zacks News
Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 9.8%
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -10.53% and 360.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Options Traders Expect Huge Moves in Aurinia (AUPH) Stock
by Zacks Equity Research
Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals (AUPH) Catches Eye: Stock Jumps 6.2%
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Options Traders Expect Huge Moves in Aurinia (AUPH) Stock
by Zacks Equity Research
Investors need to pay close attention to Aurinia (ENPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -13.33% and -45.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Aurinia Pharmaceuticals (AUPH) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 0.00% and 0.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -23.53% and 476.92%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Aurinia Pharmaceuticals (AUPH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Pharmaceuticals (AUPH) in Focus: Stock Moves 6.7% Higher
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -18.75% and 447.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
by Zacks Equity Research
Aurinia Pharmaceuticals (AUPH) needs Investors to pay close attention to the stock based on moves in the options market lately.
Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session
by Zacks Equity Research
Aurinia Pharmaceuticals saw its shares rise nearly 8% on the day.
Can The Uptrend Continue for Aurinia Pharmaceuticals (AUPH)?
by Zacks Equity Research
Investors certainly have to be happy with Aurinia Pharmaceuticals Inc (AUPH) and its short term performance
Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock
by Zacks Equity Research
Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock on the back of its high implied volatility
Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't?
by Zacks Equity Research
Investors in Aurinia Pharmaceuticals Inc. (AUPH) need to pay close attention to the stock based on moves in the options market lately.
Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store?
by Zacks Equity Research
Perrigo Company plc (PRGO) is expected to report first-quarter 2017 results later this month.
Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season?
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and Aurinia Pharmaceuticals Inc. (AUPH) may be one such company.